CFDE Data Portal | Search UQCR10

	Label	Description
	UQCR10 Gene (Entity type)	ENSG00000184076 - ubiquinol-cytochrome c reductase, complex III subunit X
	UQCR10 associations Collection (Entity type)	Associations for UQCR10_associations
	UQCR10 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE134191 3 V 1 METFORMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 4 PALMITIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 9 V 13 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE116810 5 V 1 SELINEXOR HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

UQCR10

ENSG00000184076 - ubiquinol-cytochrome c reductase, complex III subunit X

UQCR10 associations

Associations for UQCR10_associations

UQCR10 associations.tsv

A file from IDG as part of the Harmonizome project

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE216043 cisplatin 11 v 2 human dn

A Gene Set from LINCS

GSE134191 3 V 1 METFORMIN MOUSE DN

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

A Gene Set from LINCS

GSE158834 0 V 4 PALMITIC ACID HUMAN DN

A Gene Set from LINCS

GSE213588 9 V 13 TRAMETINIB HUMAN DN

A Gene Set from LINCS

GSE116810 5 V 1 SELINEXOR HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.